SCHEMBL6925885

SCHEMBL6925885

c1ccc(-c2c[nH]c(-c3ccc(N4CCCCC4)nc3)n2)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 10/20 0.56
NPC1 O15118 3/20 0.48
RAB9A P51151 3/20 0.48
SMN1; SMN2 Q16637 3/20 0.48
TSHR P16473 2/20 0.48
HPGD P15428 2/20 0.48
RECQL P46063 1/20 0.48
CNR1 P21554 1/20 0.46
HSD17B10 Q99714 4/20 0.46
USP2 O75604 1/20 0.46
LMNA P02545 1/20 0.46
HTT P42858 1/20 0.46
ALDH1A1 P00352 2/20 0.44
KMT2A Q03164 1/20 0.44
KDM4E B2RXH2 2/20 0.44
AR P10275 1/20 0.42
GAA P10253 1/20 0.42
MAPT P10636 1/20 0.42
TP53 P04637 1/20 0.42
ALOX15 P16050 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6925668 0.99 CNR2 (0.53) CNR2NPC1RAB9ASMN1; SMN2TSHR
SCHEMBL6924500 0.88 ATR (0.51) CNR2HSD17B10USP2HTTALDH1A1
SCHEMBL6926900 0.87 CNR2 (0.53) CNR2TSHRHSD17B10HTTALDH1A1
SCHEMBL6925451 0.87 FYN (0.54)
SCHEMBL6927559 0.87 RAD52 (0.44) CNR2
SCHEMBL6926636 0.86 TSHR (0.46) CNR2NPC1RAB9ASMN1; SMN2TSHR
SCHEMBL6928201 0.86 ADK (0.46) CNR2LMNAALDH1A1KMT2AKDM4E
SCHEMBL6925199 0.85 HRH3 (0.47) CNR2SMN1; SMN2TSHRHPGDHSD17B10
SCHEMBL6920359 0.85 HRH3 (0.44) CNR2HPGDHSD17B10
SCHEMBL6925622 0.84 HRH3 (0.45) SMN1; SMN2HPGDLMNAHTTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6514966-B2 Neuropeptide Y antagonists such as 2-chloro-5-(4-(3,4-dich loro-phenyl)-1H-imidazol-2-yl)-pyridine PFIZER INC. 2003-02-04 US disclosed
US-20010039277-A1 Compounds for the treatment of obesity ELLIOTT RICHARD L (US) 2001-11-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010039277-A1 Compounds for the treatment of obesity NPY1R, NPY4R, NPY2R CNR2 122/4885NPC1 1762/4885RAB9A 3108/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.